Home > News > Nanogen Expands Real-Time Portfolio
April 25th, 2006
Nanogen Expands Real-Time Portfolio
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products announced today it has expanded its molecular reagent product portfolio to include real-time probes and primers designed to detect the presence of Epstein-Barr virus (EBV). EBV is the causative agent of infectious mononucleosis and also underlies several other lymphoproliferative disorders such as Burkitt's lymphoma.
Source:
Nanogen
Bookmark:
| Related News Press |
Nanomedicine
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||